Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination chemotherapy regimens）~2. To be aged 3 to 75 years~3. Blast in blood ≤ 30%~4. ECOG score ≤2~5. Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time.~6. Voluntary participation in the clinical trials and sign the informed consent.~Exclusion Criteria:~1. Intracranial hypertension or unconsciousness~2. Respiratory failure~3. CD19 negative~4. Disseminated intravascular coagulation~5. ALT /AST\>3 x normal value; Creatinine\> 1.5 x normal value; Bilirubin \>2.0 x normal value~6. Hematosepsis or Uncontrolled active infection~7. Uncontrolled diabetes~8. Abalienation;~9. WHO Sscore \>3~10. Patients in pregnancy or breast-feeding period~11. Previously treatment with any gene therapy products~12. Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial~13. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IM19 CART (Type: EXPERIMENTAL): All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.

Based on this trial design, predict the completion outcome and termination type (if applicable).